Comparison of Hetrombopag and Eltrombopag Added to First‐Line Immunosuppressive Therapy in Severe Aplastic Anemia
European Journal of Haematology · 2025-07 · 115 (1) · 64-71
DOI: 10.1111/ejh.14418 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Haematology, online erschienen am 30.03.2025. Verfasst von Baohang Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospi…. Hauptthemen laut MEDLINE: Anemia, Aplastic, Hydrazines, Benzoates, Pyrazoles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Grant 2023-I2M-C&T-B-107 of Clinical and Translational Medicine Research Project of Chinese Academy of Medical Sciences, Grant 2022-PUMCH-C-026 of National Hig….
Abstract (Originalsprache)
The addition of thrombopoietin receptor agonists (TPO‐RAs) to immunosuppressive therapy (IST) improves the hematologic response rate and quality in patients with severe aplastic anemia (SAA). However, no studies have yet reported on whether there are differences in the efficacy of TPO‐RAs. Here, we retrospectively analyzed the clinical data of SAA patients who received hetrombopag (HPAG) or eltrombopag (EPAG) as part of first‐line standard IST to compare the efficacy. Sixty‐seven patients were enrolled in the HPAG group and 42 patients in the EPAG group. The overall hematologic response (OR) rates of the HPAG group at 3 and 6 months after IST were 50.7% and 65.6%, respectively, close to that of the EPAG group (50%, p = 0.973; 73.8%, p = 0.494). The rates of complete response (CR) at 3 and 6 months were 13.4% and 31.3% in the HPAG group, respectively, which were like those in the EPAG group (11.9% and 28.6%), with no statistical difference ( p = 1.00 and 0.59). The median time to first response (3.0 vs. 3.2 months, p = 0.79) was similar in HPAG and EPAG. The overall survival (OS) rates were 91.0% and 92.8% in the HPAG group and EPAG group ( p = 0.53), respectively. Monosomy 7 was detected in one patient in the EPAG group and her disease transformed into acute myelocytic leukemia (AML) at 25 months after ATG treatment. One patient in HPAG had trisomy 8 at 9 months of ATG treatment, and bone marrow examination showed no disease progression. Conclusion The addition of HPAG to standard IST in SAA patients showed similar response rates and response quality to that of EPAG. HPAG could be an alternative to EPAG for the first‐line treatment of SAA patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Colleg…
- Tianjin Institutes of Health Science, Tianjin, China.
ORCID-Profile: Wenrui Yang, Xiangrong Hu, Jun Shi
Förderung
- Grant 2023-I2M-C&T-B-107 of Clinical and Translational Medicine Research Project of Chinese Academy of Medical Sciences, Grant 2022-PUMCH-C-026 of National Hig…
Zitieren
APA
Zhang, B., Yang, W., Kang, R., Shi, Y., Hu, X., Zhang, L., Jing, L., Yuan, W., Shi, J., Zhang, F., & Zhao, X. (2025). Comparison of Hetrombopag and Eltrombopag Added to First‐Line Immunosuppressive Therapy in Severe Aplastic Anemia. European Journal of Haematology, 115(1), 64-71. https://doi.org/10.1111/ejh.14418
Vancouver
Zhang B, Yang W, Kang R, Shi Y, Hu X, Zhang L, et al. Comparison of Hetrombopag and Eltrombopag Added to First‐Line Immunosuppressive Therapy in Severe Aplastic Anemia. European Journal of Haematology. 2025;115(1):64-71. doi:10.1111/ejh.14418
BibTeX
@article{Zhang2025,
author = {Zhang, Baohang and Yang, Wenrui and Kang, Rui and Shi, Yimeng and Hu, Xiangrong and Zhang, Li and Jing, Liping and Yuan, Weiping and Shi, Jun and Zhang, Fengkui and Zhao, Xin},
title = {Comparison of Hetrombopag and Eltrombopag Added to First‐Line Immunosuppressive Therapy in Severe Aplastic Anemia},
journal = {European Journal of Haematology},
year = {2025},
volume = {115},
number = {1},
pages = {64--71},
doi = {10.1111/ejh.14418}
}
EUVIMED